https://www.selleckchem.com/products/sc75741.html
fects and should include patient-reported outcomes, such as comfort and acceptability. Copyright © 2020 The Cochrane Collaboration. Published by John Wiley Sons, Ltd.INTRODUCTION Higher potency is obtained with chromogenic substrate (CS) methods and one-stage (OS) method with SynthAFax vs silica-based OS methods on analysis of albutrepenonacog alpha (rFIX fused with albumin, rFIX-FP). AIM Investigation of the effect of contact activator in search for explanation of discrepancy between methods. METHODS Chromogenic Rox Factor IX met
Like
Comment
Share
